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ril 23, 2013.his study was designed to evaluate multimodal prognostication in patients after cardiac arrest (CA).Background Accurate methods to predict outcome after CA are lacking.Methods Seventy-ﬁve patients with CA treated with therapeutic hypothermia after cardiac resuscitation were enrolled in this
prospective observational study. Serum levels of neuron-speciﬁc enolase (NSE) and neuron-enriched S100 beta
(S100b) weremeasured 48 h after CA. Bispectral index (BIS) was continuouslymonitored during the ﬁrst 48 h after CA.
The primary endpoint was neurological outcome, as deﬁned by the cerebral performance category (CPC) at 6-month
follow-up: scores 1 or 2 indicated good outcome, and scores 3 to 5, poor outcome. The secondary endpointwas survival.Results A total of 46 (61%) patients survived at 6 months and 41 (55%) patients had CPC 1 or 2. Levels of NSE and S100b
were higher in patients with poor outcomes compared with patients with good outcomes (4-fold and 10-fold,
respectively; p < 0.001). BIS was lower in patients with poor outcomes (10-fold; p < 0.001). NSE, S100b, or BIS
alone predicted neurological outcome, with areas under the receiver-operating characteristic curve (AUC) above
0.80. Combined determination of S100b and BIS had an incremental predictive value (AUC: 0.95). S100b improved
discriminations based on BIS (p ¼ 0.0008), and BIS improved discriminations based on S100b (p < 10–5). Patients
with S100b level above 0.03 mg/l and BIS below 5.5 had a 3.6-fold higher risk of poor neurological outcome
(p < 0.0001). S100b and BIS predicted 6-month mortality (log-rank statistic: 50.41; p < 0.001).Conclusions Combined determination of serum level of S100b and BIS monitoring accurately predicts outcome after CA.
(J Am Coll Cardiol 2013;62:851–8) ª 2013 by the American College of Cardiology FoundationAccording to the Declaration of the European Parliament of
June 14, 2012, on establishing a European Cardiac Arrest
(CA) Awareness Week, it is estimated that some 400,000
people in Europe experience a sudden out-of-hospital CA
each year, with a survival rate around 10% (1). Survival rate
after successful cardiopulmonary resuscitation largely de-
pends on residual function of the heart and the degree of
permanent brain damage. CA is therefore a devastating
disease in terms of both morbidity and mortality.
The ability to accurately predict outcome within 48 h
of admission to the intensive care unit (ICU) in patients
resuscitated from CA would be a major achievement. Healthesia and Intensive Care, Centre Hospitalier,
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3; revised manuscript received April 11, 2013,care providers consider that this prediction would allow
a personalized therapy that would beneﬁt the patient.
Maximal cardiac supportive treatment could be applied to
patients with a possible good neurological outcome. On the
other hand, treatment could be alleviated in those with
a futile neurological prognosis. However, accurate methods
for early outcome prediction after CA are still lacking.
Initial reports of the out-of-hospital CA score (2), which
used several variables readily available at admission to the
ICU, have not been replicated (3). Neurophysiological tests
such as electroencephalography (EEG) (4–6) or somato-
sensory evoked potentials (7,8) have been suggested to
predict outcome after CA. However, while useful in some
situations, these methods are not universally applicable in
clinical practice because they require specially trained
consultants. Bispectral index (BIS) monitoring, an electro-
encephalographic monitoring method initially designed to
measure the depth of anesthesia, has some potential in
predicting brain damage after therapeutic hypothermia in
CA patients (9–11). Recently, Riker et al. (12) suggested
that BIS monitoring may aid in the identiﬁcation of patients
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852susceptible to waking up during
therapeutichypothermia.Themain
advantages of BIS monitoring are
its ease of use and therefore its
potential for widespread use.
Circulating levels of the bio-
markers neuron-speciﬁc enolase
(NSE) and neuron-enriched S100
beta (S100b) may aid in the
prognostication of outcomes after
CA (13–15). The use of NSE in
this context is recommended in
the guidelines of the American
Academy of Neurology to predict
outcomes in survivors of CA
(16). These guidelines stated that,
due to insufﬁcient data, the use
of other markers cannot be either
supported or rejected. Further-
more, most data were based onnon–hypothermia-treated patients. The 2010 European
Resuscitation Council guidelines also stipulated that, due to
a lack of evidence, biomarkers should not be used as the sole
predictors of outcome (17). For the same reason, these
guidelines also advocate greatest care when using electro-
physiological tests for prognostication.
We hypothesized that combined biomarker determination
and BIS monitoring may improve outcomes prediction in
patients resuscitated from CA.Methods
Patients. From April 2008 to July 2011, 87 patients with
CA were admitted to the 18-bed adult general ICU of an
academic tertiary care hospital in Luxembourg. Of these, 75
patients were enrolled in this prospective observational
study. The remaining 12 patients had either no blood sample
from which to measure biomarkers or were enrolled in
another ongoing study. All patients were unconscious on
admission, with a Glasgow coma score below 8. The
biomarker research protocol was approved by the national
research ethics board (National Committee for Ethics in
Research of Luxembourg). Informed consent was obtained
from all survivors or their legal representatives. Patients were
treated with hypothermia at 33C for 24 h after successful
resuscitation. All patients were sedated according to a stan-
dard sedation protocol using midazolam (maximum dosage:
0.2 mg/kg/h) and fentanyl (maximum dosage: 1.5 mg/kg/h).
A continuous infusion of cisatracurium (0.1 mg/kg/h) was
used to avoid shivering and muscular artefacts on BIS
monitoring. No patient woke up during the ﬁrst 48 h, as all
patients were sedated for at least 36 h (24 h of hypothermia
and 12 h of rewarming phase) with long-acting sedatives
(midazolam). Blood samples for biomarker determination
were drawn in citrated tubes 48 h after CA, when patients
had returned to normothermia.In patients who did not regain consciousness, no with-
drawal or withholding of any treatment was done before at
least 5 days after complete stop of sedation, unless clinical
signs of brain death were evident.
Neurological evaluation was performed before discharge
from the ICU and after 6 months. Patients were classiﬁed
according to cerebral performance category (CPC) score, as
follows: 1 or 2 ¼ no or minor neurological sequelae; 3 or
4 ¼ severe neurological sequelae or coma; and 5 ¼ death.
Measurement of serum markers. Serum level of NSE was
assessed on the Cobas e601 analyzer by the electroche-
miluminescence immunoassay method (Roche Diagnostics,
Mannheim, Germany). The lower limit of quantiﬁcation of
the assay was 0.05 mg/l. Serum level of S100b was assessed by
enzyme-linked immunosorbent assay (BioVendor, Heidel-
berg, Germany). The lower limit of quantiﬁcation of the assay
was 0.015 mg/l. S100b was measured a posteriori, with
physicians obviously blinded to the results.
Bispectral index monitoring. Since 2005, all CA patients
in our institution have undergone routine BIS XP moni-
toring with a Quatro sensor (ASPECT Medical Systems
Inc., Newton, Massachusetts), integrated to standard ICU
monitoring (IntelliVue, Philips, Böblingen, Germany) after
admission to the ICU. BIS is an EEG monitoring method
using a Fourier transformation to convert raw EEG signals
into a number from 0 (ﬂat EEG) to 100 (normal electric
activity of an awake patient). In our study, only BIS values
with a signal quality index above 80% and an electromyog-
raphy noise signal below 40 dB were used for analyses. As all
patients were paralyzed during the recording phase, muscle
artefacts (high electromyography noise) could be excluded.
BIS values were continuously recorded during the ﬁrst 48 h
after ICU admission. The lowest BIS value within this
period was used for analysis.
Statistical analysis. All analyses were preceded by the
Shapiro-Wilk normality test. Comparisons of normally
distributed data between 2 groups were performed by t test.
The nonparametric Mann-Whitney U test on ranks was
used for non-normally distributed data. Categorical data
were analyzed with the chi-square test and the Fisher exact
test. Correlation between two variables was assessed with the
Spearman test on ranks. A p value <0.05 was considered
signiﬁcant. Analyses were performed with SigmaPlot version
11.0 (Systat Software, Inc., Chicago, Illinois).
Prediction analyses were performed with the Predict-
ABLE package on the R 2.14.2 statistical platform. A p
value <0.05 was considered statistically signiﬁcant. Multiple
logistic regression models were used for the prediction of
neurological outcomes, as assessed by a binary trans-
formation of CPC (CPC 1 or 2 ¼ 0; and CPC 3–5 ¼ 1).
Multivariable analysis using multiple logistic regression
proceeding by stepwise backward elimination was used to
evaluate the predictive value of selected predictors with
respect to clinical indicators of prognosis. The area under the
receiver-operating characteristic curve (AUC) and the risk
ratios were computed to estimate predictive values. The
Table 1 Baseline Characteristics of the Study Patients
Characteristic
Good Outcome*
(n ¼ 41)
Poor Outcomey
(n ¼ 34) p Value
Age, yrs 61 (29–82) 69 (38–83) 0.01
Sex 0.69
Male 34 (83%) 23 (68%)
Female 7 (17%) 11 (32%)
SAPS II 60 (43–83) 72 (48–98) <0.001
Time to ROSC, min 20 (4–60) 30 (12–76) 0.003
Presenting rhythm
Asystole 1 (2%) 14 (41%) 0.002
PEA 2 (5%) 7 (21%) 0.08
VF/VT 36 (88%) 13 (38%) 0.05
Other 2 (5%) 0 0.50
ICU length of stay, days 17 (6–45) 9.5 (3–96) 0.01
Time to death, days 0 7 (3–109) d
Associated factors
Cardiogenic shock 11 (27%) 12 (35%) 0.74
AMI 34 (83%) 18 (53%) 0.31
EEG epileptic state 1 (2%) 10 (29%) 0.01
Seizures 2 (5%) 15 (44%) 0.003
Medical history
Tobacco 15 (37%) 8 (24%) 0.51
Alcohol abuse 4 (10%) 4 (12%) 1.00
Renal impairment 2 (5%) 4 (12%) 0.41
Hypertension 18 (44%) 19 (56%) 0.69
Heart failure 9 (22%) 12 (35%) 0.48
Coronary disease 11 (27%) 14 (41%) 0.49
Diabetes 6 (15%) 7 (21%) 0.79
CPC score at 6 months d
1 34 (83%) 0
2 7 (17%) 0
3 0 2 (6%)
4 0 3 (9%)
5 0 29 (85%)
Values are median (range) or n (%). *CPC 1 or 2 (no or minor neurological sequelae). yCPC 3–5
(severe neurological sequelae, coma, or death).
AMI ¼ acute myocardial infarction; CPC ¼ Cerebral Performance Category; EEG ¼ electroen-
cephalography; ICU ¼ intensive care unit; PEA¼ pulseless electric activity; ROSC ¼ return of
spontaneous circulation; SAPS simpliﬁed acute physiology score; VF/VT ventricular ﬁbrillation/
ventricular tachycardia.
Biomarker Levels and BIS Monitoring
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853value of adding a variable to a model was evaluated by
analysis of deviance and was tested for signiﬁcance using the
Wald chi-square test. Reclassiﬁcation analyses and integrated
discrimination improvement (IDI) were used to evaluate the
capacity of new markers to improve the discrimination of
patients misclassiﬁed by initial markers (18). Statistical
signiﬁcance was evaluated as described (19).
Survival analyses were performed using Kaplan-Meier
curves and the log-rank statistic.
Figure 1 According to Outcome
Serum levels of neuron-speciﬁc enolase (NSE) (A) and neuron-enriched S100 beta
(S100b) (B) were determined 48 h after cardiac arrest. The lowest BIS value is
presented (C). BIS ¼ bispectral index. CPC = cerebral performance category.Results
Patients. Seventy-ﬁve CA patients treated with therapeutic
hypothermia were enrolled in this study. Clinical charac-
teristics are shown in Table 1. At 6-month follow-up, 41
patients (55%) had a good neurological outcome (CPC 1 or
2), and 34 patients had a poor outcome (CPC 3–5). Of the
latter, 29 patients died during follow-up. The sex ratio wassimilar between patients with good and poor outcomes.
Patients with poor outcomes were older. Clinical parameters
potentially reﬂecting disease severity (simpliﬁed acute
Figure 2
Prediction of Neurological Outcome by
Serum Markers and BIS Monitoring
S100b and NSE measured 48 h after cardiac arrest, and BIS monitoring, were
used as inputs to multiple logistic regression models for the prediction of 6-month
CPC. (A) Receiver-operating characteristic (ROC) curves for single markers. (B)
ROC curves for combinations of markers. The areas under the ROC curve (AUC) are
indicated. CI ¼ conﬁdence interval; other abbreviations as in Figure 1.
Table 2 Reclassiﬁcation Analyses
Initial Model
Variable Added to
the Initial Model IDI (95% CI) p Value
BIS monitoring S100b 0.13 (0.05 to 0.21) 0.0008
S100b BIS monitoring 0.32 (0.22 to 0.43) <0.00001
BIS and S100b NSE 0.02 (–0.01 to 0.06) 0.24
NSE BIS 0.14 (0.06 to 0.21) 0.0005
NSE BIS and S100b 0.20 (0.11 to 0.28) <0.00001
BIS ¼ bispectral index; CI ¼ conﬁdence interval; IDI ¼ integrated discrimination improvement;
NSE ¼ neuron-speciﬁc enolase; S100b ¼ neuron-enriched S100 beta.
Stammet et al. JACC Vol. 62, No. 9, 2013
Prediction of Outcome After Cardiac Arrest August 27, 2013:851–8
854physiology score [SAPS II], time from CA to return of
spontaneous circulation [ROSC]) were higher in the poor-
outcomes group.
Serum biomarker levels and BIS monitoring. Forty-eight
hours after CA, serum levels of NSE and S100b were
signiﬁcantly higher in patients with poor outcomes
compared with those in patients with good outcomes (4-
fold and 10-fold, respectively; p < 0.001) (Figs. 1A and
1B). Of note, serum levels of NSE and S100b were highly
correlated (r: 0.61; p ¼ 4  10–11). BIS was higher in
patients with good outcomes compared with that in patients
with poor outcomes (10-fold; p < 0.001) (Fig. 1C). The
median time until the lowest BIS value was 5 h (range: 4 to
14.5 h) after CA.
Prediction of neurological outcome by serum markers
and BIS monitoring. Logistic regression was used to
determine the ability of serum markers NSE and S100b
measured 48 h after CA, and of the lowest value of BIS to
predict neurological outcomes at 6 months, as dichotomized
by CPC 1 or 2 and CPC 3 to 5. S100b, NSE, and BIS had
signiﬁcant predictive values, with AUCs above 0.80
(Fig. 2A). Combined determination of S100b and BIS had
an incremental predictive value, with an AUC of 0.95.
Combination of S100b and NSE, or BIS and NSE, had
lower predictive values (Fig. 2B). Adding NSE to S100b
and BIS did not further improve the prediction (Fig. 2B).
Analysis of deviance conﬁrmed that the addition of S100b
to the model with BIS improved the prediction (deviance:
16.3; p ¼ 5  10–5). However, the addition of NSE to the
model with S100b and BIS did not improve prediction
(deviance: 2.7; p ¼ 0.10).
Reclassiﬁcation analyses were then performed to address
the additive value of biomarkers and BIS (Table 2). First, we
assessed the additive value of S100b to BIS monitoring.
S100b improved the discrimination based on BIS moni-
toring (IDI ¼ 0.13; p ¼ 0.0008). On the other hand, BIS
improved the discrimination based on S100b, with an IDI
of 0.32 (p < 10–5). NSE failed to improve the discrimina-
tion of patients misclassiﬁed by a model including BIS and
S100b. BIS improved the classiﬁcation of NSE (IDI ¼ 0.14;
p ¼ 0.0005). A model with BIS with S100b also improved
the classiﬁcation of NSE (IDI ¼ 0.20; p < 10–5).
Therefore, together, serum level of S100b and BIS
monitoring are robust predictors of neurological outcomes
after CA.
Cutoffs for the prediction of neurological outcomes by
S100b and BIS monitoring. We ﬁrst determined the
cutoffs for S100b and BIS monitoring, which provide the best
compromise between sensitivity and speciﬁcity for the
prediction of neurological outcomes (Figs. 3A and 3B). The
cutoff for S100b was 0.03 mg/l, providing a sensitivity of 76%,
a speciﬁcity of 78%, and a false positive rate of 22%. The
cutoff for BIS was 5.5, providing a sensitivity of 85%,
a speciﬁcity of 83%, and a false positive rate of 17%. Risk
ratios of poor neurological outcome were calculated
(Fig. 3C). Patients with a S100b serum level above 0.03 mg/l(n ¼ 33) had a 3.4-fold higher risk of poor neurological
outcomes (95% conﬁdence interval [CI]: 1.88 to 6.34; p <
0.0001). Patients with BIS monitoring below 5.5 (n ¼ 36)
had a 6.1-fold higher risk of poor neurological outcomes
Figure 3 Optimal Cutoffs of S100b and BIS and Risk Ratios for Prediction of Neurological Outcome
(A and B) Cutoffs were determined by plotting sensitivity versus speciﬁcity values, and are indicated by dotted lines and italicized values. (C and D) Risk ratios of poor
neurological outcome (CPC 3–5) according to cutoff values for S100b and BIS. The dotted vertical line indicates a risk ratio of 1. Risk ratios  95% CI are presented.
Abbreviations as in Figures 1 and 2.
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855(95% CI: 2.66 to 10.07; p < 0.0001). Patients with both
serum level of S100b above 0.03 mg/l and BIS monitoring
below 5.5 (n ¼ 21) had a 3.6-fold higher risk of poor
neurological outcome (95% CI: 2.28 to 5.71; p < 0.0001).
Second, we determined the cutoff values for optimal
prediction of poor outcome. A level of S100b above 0.3 mg/l
predicted a poor outcome with a speciﬁcity of 100%. A BIS
value of 0 predicted a poor outcome with a speciﬁcity of 90%
and a false positive rate of 10%. As shown in Figure 3D,
patients with a S100b level above 0.3 mg/l (n ¼ 7) had a 2.5-
fold higher risk of poor neurological outcome (95% CI: 1.85
to 3.32; p ¼ 0.003). Patients with a BIS value of 0 (n ¼ 31)
had a 5.3-fold higher risk of poor neurological outcome (95%
CI: 2.68 to 10.68; p < 0.0001). Patients with S100b level
above 0.3 mg/l and a BIS value of 0 (n ¼ 6) had a 2.4-fold
higher risk of poor neurological outcomes (95% CI: 1.83 to
3.23; p ¼ 0.007).
Prediction of mortality by S100b and BIS monitoring.
Average survival time for patients who died during follow-up
(n ¼ 29) was 18 days (range: 3 to 107 days). Survival curves
are shown in Figure 4. Patients with a serum level of S100b
above the cutoff value of 0.03 mg/l were at a high risk ofdeath during follow-up (log-rank statistic: 17.17; p <
0.001). Patients with a BIS value below the cutoff value of
5.5 were at high risk of death during follow-up (log-rank
statistic: 35.79; p < 0.001). Patients with a serum level of
S100b above the cutoff value of 0.03 mg/l and a BIS value
below the cutoff value of 5.5 were at a high risk of death
during follow-up (log-rank statistic: 50.41; p < 0.001).
Therefore, serum level of S100b and BIS monitoring are
strong predictors of mortality after CA.
Added value of S100b and BIS to traditional prognostic
indicators. Finally, we evaluated the predictive value of
S100b and BIS with respect to other clinical indicators of
prognosis: age; sex; SAPS II; time to ROSC; presenting
rhythm (asystole/pulseless electric activity vs. ventricular
ﬁbrillation/ventricular tachycardia); and associated factors
such as cardiogenic shock, acute myocardial infarction, EEG
epileptic state, and seizures. Multivariable analyses showed
that SAPS II (p ¼ 0.04), presenting rhythm (p ¼ 0.01),
S100b (p ¼ 0.01), and BIS (p ¼ 0.01) were independent
predictors of neurological outcome. Reclassiﬁcation analyses
attested that S100b and BIS were able to improve the
discrimination based on SAPS II and presenting rhythm
Figure 4 Survival Analyses
Kaplan-Meier curves showing the survival of patients according to their serum level
of S100b (A), BIS monitoring (B), or both (C). Abbreviations as in Figure 1.
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856with an IDI of 0.22 (p ¼ 10–5). Therefore, combined
determination of S100b and BIS improves the prediction of
outcome by SAPS II and presenting rhythm.Discussion
We identiﬁed a method to accurately predict neurological
outcome and survival after CA. This method relies on the
measurement of serum levels of S100b and BIS monitoring.
While these two markers have previously been considered as
potential predictors of outcome after CA, this study is the
ﬁrst to report that combined determination of both markers
has an incremental, and very robust, prognostic value.
The patients enrolled in this study were all resuscitated
from CA and treated by therapeutic hypothermia. Due to the
dichotomization of patients into good- and poor-outcomes
groups, certain disease-related parameters obviously differed
between groups. But, as discussed previously, those criteria
alone are not sufﬁcient to prognosticate outcome (2,20). Thus,
the impact of our results should not be affected by the
signiﬁcant differences between the 2 groups of patients.
Booth et al. (20) identiﬁed from a review of the existing
literature 4 clinical indicators that predict death or poor
neurological outcome of comatose survivors of CA: absent
corneal reﬂexes, pupillary response, withdrawal response to
pain, and motor response at 24 h. These ﬁndings suggested
that routine clinical examination could predict outcome.
However, the studies included in this meta-analysis were
performed before 2003, a time when therapeutic hypo-
thermia was not generally performed. In addition, the
authors pointed out that clinical examination alone was
insufﬁcient to predict prognosis and should be coupled with
other tests or biological markers.
The calcium-binding protein S100b is enriched in astro-
glial cells and can cross the blood–brain barrier after hypoxic
damage of the central nervous system. Its routine measure-
ment is simple and relatively inexpensive. S100b is ﬁltrated
by the kidney (21) and has an estimated half-life of 2 h (22).
Its serum level increases after CA, and its prognostic value
has been studied (23–28). Because of mitigated results, its
routine use has been, up to now, not recommended (16).
EEG ﬁndings during hypothermia correlate with neuronal
injury post–brain anoxia (29). Amplitude-integrated EEG
certainly has some potential for outcome prediction, but this
technique, as well as classic EEG, generally require expertise
and special training or consultant support (6). On the other
hand, BIS monitoring, which is easily done, appears to be
useful to predict outcome after CA (9–11,30). Interestingly,
in our study, the lowest values of BIS used for outcome
prediction occurred after 5 h (median value), indicating that
BIS has the potential for very early prognostication.
NSE has a role in glucose metabolism. As for S100b,
NSE is released from the hypoxic brain into the blood-
stream, and its serum level correlates with the extent of brain
injury. Also, NSE correlates with other markers of brain
injury (31). NSE has a high speciﬁcity to predict adverse
outcomes when measured in the few days post CA (26,32).
A cutoff point of 33 mg/l is recommended (16). In our study,
the speciﬁcity obtained with this cutoff was 83%. NSE levels
before 24 h post CA should not be used for prognostication,
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measured 48 h post CA. From our results, the predictive
value of NSE and its potential contribution to a multimarker
strategy remain uncertain. Indeed, analysis of ROC curves
showed a maximal AUC for NSE of 0.90, albeit very close to
the AUC of BIS (0.89). However, analysis of deviance and
reclassiﬁcation analyses attested that NSE did not increase
the predictive value of the model with S100b and BIS. This
is probably related to the fact that NSE and S100b are both
originating from the brain and do not provide independent
information. Consistently, a high correlation was found
between serum levels of these two markers. These observa-
tions are consistent with those from the study by Einav et al.
(26), in which NSE was not an independent predictor of
outcome (26). Interestingly, in this same study, S100b was
an independent predictor of outcome, and this is in line with
our ﬁndings. The prognostic performance of NSE, alone or
combined with other markers, deserves further testing.
While a cutoff value of 33 mg/l is generally accepted for
NSE, there is to date no consensus on the cutoff value for
S100b. In our study, a cutoff value of 0.03 mg/l of S100b was
found to predict neurological outcomes with a sensitivity of
76% and a speciﬁcity of 78%. This cutoff value is lower than
the cutoff values reported by Einav et al. (26), which ranged
from 0.2 to 100 mg/l, depending on the presenting rhythm of
the patients, their age, and the time of blood sampling. It
should be noted that not all patients in the study by Einav et al.
were treated with therapeutic hypothermia, which may explain
the higher cutoff values obtained in that study compared to our
study. In the study by Mortberg et al. (33), a cutoff value of
0.18 mg/l was retained. In the study by Rundgren et al. (13),
levels of S100b above 0.51 mg/l at 24 h predicted poor
outcome with a speciﬁcity of 96%. In those three studies, the
cutoff values were chosen for the prediction of poor outcome,
while our cutoff value of 0.03 mg/l was chosen to provide the
most accurate prediction of both poor and good outcomes. In
a second phase, we observed that a cutoff value of 0.3 mg/l
predicted poor outcome with a speciﬁcity of 100%, meaning
that all patients with a S100b level above 0.3 mg/l had a poor
outcome. This cutoff, which is in line with those from previous
studies (13,26,33), suggests that a single determination of
S100b would be sufﬁcient to establish a secure prognostic.
However, this speculation is limited by the few patients pre-
senting with such a high level of S100b. Overall, the cutoff
values of S100b remain to be determined in larger populations,
taking into account the demographic and clinical characteristics
of each individual patient.
Although an accurate and reliable method to prognosti-
cate patients with CA is still needed, several indicators of
prognosis are available to the treating physician. In our
group of patients, SAPS II and presenting rhythm were
signiﬁcant predictors of neurological outcome. Interestingly,
we observed that combined determination of S100b and BIS
had an incremental predictive value.
Study limitations. First, we must acknowledge that BIS is
a processed EEG signal that monitors only a limited area ofthe brain and not the whole cortex, as standard EEG does. In
order to eliminate electromyography artefacts, the patients
have to be under neuromuscular blockade, at least during the
ﬁrst hours of BIS measurements. Furthermore, although
a continuous EEG tracing is shown on the monitoring, it is
not suitable for detection of any particular EEG patterns, such
as burst suppression or epileptic state. Standard EEG is still
required for the diagnosis and subsequent treatment of these
disorders. Second, the treating physicians were not blinded to
our BIS data or NSE values. However, as pointed out by our
study protocol, withdrawal or withholding of treatment was
done only 5 days after the cessation of sedation. Complete
blinding to BIS data is complex because accurate measure-
ments require frequent signal-quality checks to correct elec-
trode application, for instance. Blinding of the treating
physician would require a third person to check the accuracy of
the BIS monitoring nearly continuously. Furthermore, the
BIS data must be masked on the monitoring system and in
the patient data chart, which is automatically linked to the
monitoring system. This was not feasible in the current study.
In contrast, treating physicians were blinded to S100b because
it was a completely a posteriori analysis. Third, CPC deter-
mination can be subjective (34). However, this does not
represent a major limitation of our study because 85% of
patients with a poor CPC had died by the 6-month follow-up.
Fourth, the distributions of S100b and BIS were left censored
at 0 because 41% of patients had no EEG activity (BIS ¼ 0)
and 24% had a S100b level below the detection limit of the
assay. However, this censoring does not diminish the predic-
tive value of these markers because it does not affect c statistic.
Fifth, the small size of the study population did not allow
accurate determination of the prognostic value of each of the
nine clinical predictors included in the multivariable analyses.
Conclusions
Using a biochemical and an electrophysiological marker of
brain damage, outcomes after CA may be predicted. Further
studies are required to conﬁrm our ﬁndings.
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